Size | Price | Stock | Qty |
---|---|---|---|
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Labetalol HCl (ch15719W; AH5158; Normodyne, Albetol, Trandate, Apo-Labetalol, Dilevalol), the hydrochloride salt of Labetalol, is a competitive and dual antagonist of alpha1-adrenergic and beta-adrenergic receptors with potential antihypertensive properties. The medication labetalol was approved to treat hypertension.
Targets |
α1-adrenergic receptor; β-adrenergic receptor
|
---|---|
Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation Because of the low levels of labetalol in breastmilk, amounts ingested by the infant are small and would not be expected to cause any adverse effects in fullterm breastfed infants. No special precautions are required in most infants. However, other agents may be preferred while nursing a preterm infant. Labetalol may predispose nursing mothers to Raynaud’s phenomenon of the nipple. ◉ Effects in Breastfed Infants One investigator reported that no adverse effects occurred in breastfed infants whose mothers were taking labetalol in doses of 330 to 800 mg daily. A 26-week premature infant weighing 640 grams developed sinus bradycardia (80 to 90 bpm) and isolated atrial premature beats after nasogastric feeding with mother's pumped breastmilk began on day 8 of life. The mother was taking labetalol 300 mg twice daily by mouth for hypertension. Bradycardia and premature beats resolved within 24 hours of substitution of formula for breastmilk. No other causes for bradycardia could be identified. One untimed sample of the mother's breastmilk contained 710 mcg/L of labetalol. Although the authors estimated the infant's dose to be 100 mg/kg daily, a recalculation using their data indicates that the infant's dose was only 100 mcg/kg daily. A 2-month-old infant was being breastfed exclusively by a mother taking labetalol 100 mg twice daily. The infants electrocardiogram had a regular heart rate, but borderline prolonged QT. The infant was started on propranolol 1 mg/kg daily for infantile hemangioma. One month later, the infant had a normal QT interval. A second infant was exclusively breastfed by a mother taking labetalol 150 mg twice daily and nifedipine 60 mg daily. The infant was started on propranolol 0.6 mg/kg daily for infantile hemangioma. The propranolol dose was increased over 2 weeks to 3.4 mg/kg daily. The infant had some sleeping difficulties with the higher propranolol dose, but no other symptoms. ◉ Effects on Lactation and Breastmilk Intravenous labetalol can increase serum prolactin in men and non-nursing women, although the increase is greater in women. Oral labetalol does not increase serum prolactin. The maternal prolactin level in a mother with established lactation may not affect her ability to breastfeed. A woman with a history of symptoms of Raynaud's phenomenon developed Raynaud's phenomenon of the nipples when treated for pregnancy-induced hypertension with labetalol 100 mg twice daily. She breastfed for 5 weeks, but nursing caused pain in her nipples. In a subsequent pregnancy, similar symptoms occurred during treatment with labetalol 100 mg twice daily. Discontinuing labetalol eliminated the nipple pain in both instances. A pregnant woman was treated on two occasions with intravenous labetalol for pre-eclampsia. On each occasion, she reported a burning sensation of the nipples. While continuing on labetalol, sustained-release nifedipine was added to her regimen and the burning of the nipple did not return. |
References | |
Additional Infomation |
Labetalol hydrochloride is a member of salicylamides.
Labetalol Hydrochloride is the hydrochloride form of labetalol, a third generation selective alpha-1-adrenergic antagonist and non-selective beta-adrenergic antagonist with vasodilatory and antihypertensive properties. Labetalol competitively binds to alpha-1-adrenergic receptors in vascular smooth muscle, thereby inhibiting the adrenergic stimulation of endothelial cell function and vasoconstriction in peripheral blood vessels. This agent also binds to beta-receptors in the bronchial and vascular smooth muscle, resulting in a decrease in adrenergic stimulation. The result is a decrease in resting and exercise heart rates, cardiac output, and in both systolic and diastolic blood pressure, thereby resulting in vasodilation, and negative chronotropic and inotropic cardiac effects. A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS. See also: Labetalol (has active moiety); Hydrochlorothiazide; labetalol hydrochloride (component of). |
Molecular Formula |
C19H25CLN2O3
|
---|---|
Molecular Weight |
364.866404294968
|
Exact Mass |
364.16
|
Elemental Analysis |
C, 62.55; H, 6.91; Cl, 9.72; N, 7.68; O, 13.15
|
CAS # |
32780-64-6
|
Related CAS # |
Labetalol; 36894-69-6; Labetalol hydrochloride (Standard); 32780-64-6
|
PubChem CID |
71412
|
Appearance |
White to off-white crystalline powder
|
Density |
1.2±0.1 g/cm3
|
Boiling Point |
552.7±50.0 °C at 760 mmHg
|
Melting Point |
187-189°
|
Flash Point |
288.1±30.1 °C
|
Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
Index of Refraction |
1.609
|
LogP |
2.31
|
Hydrogen Bond Donor Count |
5
|
Hydrogen Bond Acceptor Count |
4
|
Rotatable Bond Count |
8
|
Heavy Atom Count |
25
|
Complexity |
385
|
Defined Atom Stereocenter Count |
0
|
SMILES |
O=C(N)C1=CC(C(O)CNC(C)CCC2=CC=CC=C2)=CC=C1O.[H]Cl
|
InChi Key |
WQVZLXWQESQGIF-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C19H24N2O3.ClH/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24;/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24);1H
|
Chemical Name |
2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide;hydrochloride
|
Synonyms |
AH-5158 hydrochloride; Sch-15719W; AH5158 hydrochloride; Sch15719W; AH 5158 hydrochloride; Sch 15719W; Normodyne; Trandate; Albetol; Apo-Labetalol; Dilevalol
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.85 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.85 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.85 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.7407 mL | 13.7035 mL | 27.4070 mL | |
5 mM | 0.5481 mL | 2.7407 mL | 5.4814 mL | |
10 mM | 0.2741 mL | 1.3704 mL | 2.7407 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05551104 | Recruiting | Drug: Oral Nifedipine Drug: Oral Labetalol |
Postpartum Complication Maternal Hypertension |
Loma Linda University | December 2023 | Not Applicable |
NCT04298034 | Recruiting | Drug: Labetalol, Nifedipine | Preeclampsia Hypertension in Pregnancy |
Medical College of Wisconsin | July 17, 2020 | Phase 3 |
NCT04755764 | Recruiting | Drug: Labetalol Drug: Atenolol Drug: Nifedipine |
Systolic Hypertension Pregnancy Related |
Marshall University | March 3, 2021 | N/A |
NCT05309460 | Not yet recruiting | Drug: Labetalol Oral Tablet Drug: NIFEdipine ER |
Postpartum Preeclampsia Hypertension in Pregnancy |
Nebraska Methodist Health System |
June 6, 2022 | Phase 4 |
NCT06093893 | Not yet recruiting | Drug: Dexmedetomidine Drug: Nicardipine |
Hypotensive Anesthesia Orthognathic Surgery |
Boston Medical Center | March 2024 | Phase 4 |